OR WAIT null SECS
The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.
Emergent BioSolutions announced on June 18, 2020 that it will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing (CDMO) capabilities.
According to a company press release, the investment will include a state-of-the-art, multi-suite operation up to 1000-L scale. The investment also aligns with the company’s five-year growth plan which involves offering development services out of its Gaithersburg, MD, location, drug substance manufacturing out of Canton, and drug product manufacturing at its Rockville, MD, location.
“Emergent’s expansion into advanced therapy CDMO services is based on our biologics expertise and a strong understanding of our customers’ current and future needs,” said Sean Kirk, executive vice-president, manufacturing, and technical operations at Emergent BioSolutions, in the press release. “We are investing in our people, plants, and products to meet the growing demand for precision treatments and to help get these therapies to patients.”
“We are energized by the continued growth of our CDMO offerings and this new focus on advanced therapies,” added Syed T. Husain, senior vice-president and CDMO business unit head, in the press release. “As a leading CDMO service provider, our goal is to support the needs of industry and fellow innovators in line with our mission-to protect and enhance life.”